Chiara Fischer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chiara Fischer has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Daniel Hartkopf
Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
4 shared publications - Andreas Schneeweiss
National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
4 shared publications - Markus Wallwiener
Department of Gynecology, University Hospital Halle, Halle, Germany
4 shared publications - Thomas Maximilian Deutsch
Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany
4 shared publications - Manuel Feisst
Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany
3 shared publications - Sara Yvonne Brucker
Department of Gynecology and Obstetrics, University Hospital Tübingen, Tübingen, Germany
3 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (12) , 1616-1632
S1‐Leitlinie für bildgebende Diagnostik von Hauterkrankungen
Zusammenfassung: Nichtinvasive Bildgebungstechniken erlauben schnell und schmerzfrei diagnostische Blicke in die Haut, je nach angewandter Methode mit unterschiedlich hoher Auflösung und Eindringtiefe. Schon seit Jahrzehnten aus dem Alltag nicht wegzudenken sind die etablierten Untersuchungsmethoden wie die Dermatoskopie und die hochauflösende Sonographie der Haut und Subkutis. Weitere innovative Verfahren wie die optische Kohärenztomographie (OCT), die konfokale Lasermikroskopie (KLM) und die Line‐field konfokale OCT ( Line‐field confocal OCT ; LC‐OCT), die die Untersuchung der Haut mit sehr hoher Auflösung erlauben, haben Einzug in die klinische Routine gehalten. Die Multiphotonentomographie sowie die optoakustische Bildgebung gelten ebenfalls als vielversprechende neuere Verfahren. Neben den nichtinvasiven Verfahren, die in vivo direkt am Patienten zum Einsatz kommen, können die KLM und die LC‐OCT auch ex vivo an exzidiertem Gewebe zur Schnellschnittdiagnostik angewendet werden. Die bei allen Bildgebungsmethoden generierten Daten eignen sich hervorragend für die Anwendung KI‐basierter Algorithmen zur Erhöhung der diagnostischen Treffsicherheit und Unterstützung des erfahrenen Anwenders. Alle genannten Verfahren haben ihre Stärken, Limitationen und bevorzugte Indikationen. Im Folgenden wird ein Überblick über die verschiedenen Geräte und Techniken gegeben und für jede Methode die Funktionsweise und die aktuelle Studienlage zu Indikationen und Grenzen des jeweiligen Verfahrens dargelegt.
- 11 December 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (12) , 1616-1632
Open AccessS1‐Leitlinie für bildgebende Diagnostik von Hauterkrankungen
Zusammenfassung: Nichtinvasive Bildgebungstechniken erlauben schnell und schmerzfrei diagnostische Blicke in die Haut, je nach angewandter Methode mit unterschiedlich hoher Auflösung und Eindringtiefe. Schon seit Jahrzehnten aus dem Alltag nicht wegzudenken sind die etablierten Untersuchungsmethoden wie die Dermatoskopie und die hochauflösende Sonographie der Haut und Subkutis. Weitere innovative Verfahren wie die optische Kohärenztomographie (OCT), die konfokale Lasermikroskopie (KLM) und die Line‐field konfokale OCT ( Line‐field confocal OCT ; LC‐OCT), die die Untersuchung der Haut mit sehr hoher Auflösung erlauben, haben Einzug in die klinische Routine gehalten. Die Multiphotonentomographie sowie die optoakustische Bildgebung gelten ebenfalls als vielversprechende neuere Verfahren. Neben den nichtinvasiven Verfahren, die in vivo direkt am Patienten zum Einsatz kommen, können die KLM und die LC‐OCT auch ex vivo an exzidiertem Gewebe zur Schnellschnittdiagnostik angewendet werden. Die bei allen Bildgebungsmethoden generierten Daten eignen sich hervorragend für die Anwendung KI‐basierter Algorithmen zur Erhöhung der diagnostischen Treffsicherheit und Unterstützung des erfahrenen Anwenders. Alle genannten Verfahren haben ihre Stärken, Limitationen und bevorzugte Indikationen. Im Folgenden wird ein Überblick über die verschiedenen Geräte und Techniken gegeben und für jede Methode die Funktionsweise und die aktuelle Studienlage zu Indikationen und Grenzen des jeweiligen Verfahrens dargelegt.
- Open Access
- 16 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (12) , 1616-1630
S1 guideline for imaging diagnostics for skin diseases
Summary: Non‐invasive imaging techniques allow a quick and easy in vivo examination of the skin with different penetration depths and resolution depending on the applied technology. Established methods such as dermoscopy and high‐resolution sonography of the skin have been an integral part of everyday life for decades. Additionally, new emerging techniques such as optical coherence tomography (OCT), reflectance confocal microscopy (RCM), and line‐field confocal OCT (LC‐OCT) have entered clinical practice. Multiphoton tomography and optoacoustic imaging are also considered promising new methods. RCM and LC‐OCT can also be used ex vivo on freshly excised tissue, for example in Moh's surgery margin assessment. The data generated by all imaging methods is ideal for the application of AI‐based algorithms to increase diagnostic accuracy and support experienced users. All mentioned methods have preferred indications depending on their strengths and limitations, both in skin tumor diagnostics and in inflammatory, infectious and parasitic dermatoses. The following guideline provides an overview of the various devices and techniques, explains how each method works and provides the current study situation with indications and limitations of each procedure.
- 16 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (12) , 1616-1630
Open AccessS1 guideline for imaging diagnostics for skin diseases
Summary: Non‐invasive imaging techniques allow a quick and easy in vivo examination of the skin with different penetration depths and resolution depending on the applied technology. Established methods such as dermoscopy and high‐resolution sonography of the skin have been an integral part of everyday life for decades. Additionally, new emerging techniques such as optical coherence tomography (OCT), reflectance confocal microscopy (RCM), and line‐field confocal OCT (LC‐OCT) have entered clinical practice. Multiphoton tomography and optoacoustic imaging are also considered promising new methods. RCM and LC‐OCT can also be used ex vivo on freshly excised tissue, for example in Moh's surgery margin assessment. The data generated by all imaging methods is ideal for the application of AI‐based algorithms to increase diagnostic accuracy and support experienced users. All mentioned methods have preferred indications depending on their strengths and limitations, both in skin tumor diagnostics and in inflammatory, infectious and parasitic dermatoses. The following guideline provides an overview of the various devices and techniques, explains how each method works and provides the current study situation with indications and limitations of each procedure.
- Open Access
- 19 January 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Medical Imaging
- Vol. 43 (6) , 2074-2085
Machine Learning Analysis of Human Skin by Optoacoustic Mesoscopy for Automated Extraction of Psoriasis and Aging Biomarkers
Ultra-wideband raster-scan optoacoustic mesoscopy (RSOM) is a novel modality that has demonstrated unprecedented ability to visualize epidermal and dermal structures in-vivo . However, an automatic and quantitative analysis of three-dimensional RSOM datasets remains unexplored. In this work we present our framework: Deep Learning RSOM Analysis Pipeline (DeepRAP), to analyze and quantify morphological skin features recorded by RSOM and extract imaging biomarkers for disease characterization. DeepRAP uses a multi-network segmentation strategy based on convolutional neural networks with transfer learning. This strategy enabled the automatic recognition of skin layers and subsequent segmentation of dermal microvasculature with an accuracy equivalent to human assessment. DeepRAP was validated against manual segmentation on 25 psoriasis patients under treatment and our biomarker extraction was shown to characterize disease severity and progression well with a strong correlation to physician evaluation and histology. In a unique validation experiment, we applied DeepRAP in a time series sequence of occlusion-induced hyperemia from 10 healthy volunteers. We observe how the biomarkers decrease and recover during the occlusion and release process, demonstrating accurate performance and reproducibility of DeepRAP. Furthermore, we analyzed a cohort of 75 volunteers and defined a relationship between aging and microvascular features in-vivo . More precisely, this study revealed that fine microvascular features in the dermal layer have the strongest correlation to age. The ability of our newly developed framework to enable the rapid study of human skin morphology and microvasculature in-vivo promises to replace biopsy studies, increasing the translational potential of RSOM.
- 19 January 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Medical Imaging
- Vol. 43 (6) , 2074-2085
Open AccessMachine Learning Analysis of Human Skin by Optoacoustic Mesoscopy for Automated Extraction of Psoriasis and Aging Biomarkers
Ultra-wideband raster-scan optoacoustic mesoscopy (RSOM) is a novel modality that has demonstrated unprecedented ability to visualize epidermal and dermal structures in-vivo . However, an automatic and quantitative analysis of three-dimensional RSOM datasets remains unexplored. In this work we present our framework: Deep Learning RSOM Analysis Pipeline (DeepRAP), to analyze and quantify morphological skin features recorded by RSOM and extract imaging biomarkers for disease characterization. DeepRAP uses a multi-network segmentation strategy based on convolutional neural networks with transfer learning. This strategy enabled the automatic recognition of skin layers and subsequent segmentation of dermal microvasculature with an accuracy equivalent to human assessment. DeepRAP was validated against manual segmentation on 25 psoriasis patients under treatment and our biomarker extraction was shown to characterize disease severity and progression well with a strong correlation to physician evaluation and histology. In a unique validation experiment, we applied DeepRAP in a time series sequence of occlusion-induced hyperemia from 10 healthy volunteers. We observe how the biomarkers decrease and recover during the occlusion and release process, demonstrating accurate performance and reproducibility of DeepRAP. Furthermore, we analyzed a cohort of 75 volunteers and defined a relationship between aging and microvascular features in-vivo . More precisely, this study revealed that fine microvascular features in the dermal layer have the strongest correlation to age. The ability of our newly developed framework to enable the rapid study of human skin morphology and microvasculature in-vivo promises to replace biopsy studies, increasing the translational potential of RSOM.
- Open Access
- 23 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (17) , 9535
Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic and predictive biomarker in metastatic breast cancer (MBC). Expression levels of the plasma miR-200 family were analyzed in relationship to systemic treatment, circulating tumor cells (CTC) count, progression-free survival (PFS), and overall survival (OS). Expression of miR-200a, miR-200b, miR-200c, miR-141, and miR-429, and CTC status (CTC-positive ≥ 5 CTC/7.5 mL) was assessed in 47 patients at baseline (BL), after the first completed cycle of a new line of systemic therapy (1C), and upon the progression of disease (PD). MiR-200a, miR-200b, and miR-141 expression was reduced at 1C compared to BL. Upon PD, all miR-200s were upregulated compared to 1C. At all timepoints, the levels of miR-200s were elevated in CTC-positive versus CTC-negative patients. Further, heightened miR-200s expression and positive CTC status were associated with poorer OS at BL and 1C. In MBC patients, circulating miR-200 family members decreased after one cycle of a new line of systemic therapy, were elevated during PD, and were indicative of CTC status. Notably, increased levels of miR-200s and elevated CTC count correlated with poorer OS and PFS. As such, both are promising biomarkers for optimizing the clinical management of MBC.
- 23 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (17) , 9535
Open AccessCirculating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic and predictive biomarker in metastatic breast cancer (MBC). Expression levels of the plasma miR-200 family were analyzed in relationship to systemic treatment, circulating tumor cells (CTC) count, progression-free survival (PFS), and overall survival (OS). Expression of miR-200a, miR-200b, miR-200c, miR-141, and miR-429, and CTC status (CTC-positive ≥ 5 CTC/7.5 mL) was assessed in 47 patients at baseline (BL), after the first completed cycle of a new line of systemic therapy (1C), and upon the progression of disease (PD). MiR-200a, miR-200b, and miR-141 expression was reduced at 1C compared to BL. Upon PD, all miR-200s were upregulated compared to 1C. At all timepoints, the levels of miR-200s were elevated in CTC-positive versus CTC-negative patients. Further, heightened miR-200s expression and positive CTC status were associated with poorer OS at BL and 1C. In MBC patients, circulating miR-200 family members decreased after one cycle of a new line of systemic therapy, were elevated during PD, and were indicative of CTC status. Notably, increased levels of miR-200s and elevated CTC count correlated with poorer OS and PFS. As such, both are promising biomarkers for optimizing the clinical management of MBC.
- Open Access
- 1 July 2020
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 183 (1) , 137-144
Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
Background: The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses are frequently discordant between the primary tumor and metastatic lesions in metastatic breast cancer. This can have important therapeutic implications. Patients and methods: In all, 541 patients with available receptor statuses from both primary tumor and metastatic lesion treated at Heidelberg and Tuebingen University Hospitals between 1982 and 2018 were included. Results: Statistically significant discordance rates of 14% and 32% were found for ER and PR. HER2 status was statistically insignificantly discordant in 15% of patients. Gain in HER2 positivity was associated with an improved overall survival, whereas loss of HR positivity was associated with worse overall survival. Antiendocrine treatment differed in 20% of cases before and after biopsy and HER2-directed treatment in 14% of cases. Conclusions: Receptor statuses are discordant between primary tumor and metastasis in a considerable fraction of patients with metastatic breast cancer. Next to a highly presumed predictive value with respect to efficacy of endocrine and HER2-targeted therapy, discordance seems to provide prognostically relevant information. Where feasible, metastatic lesions should be biopsied in accordance with current guidelines.
- 1 July 2020
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 183 (1) , 137-144
Open AccessEstrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
Background: The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses are frequently discordant between the primary tumor and metastatic lesions in metastatic breast cancer. This can have important therapeutic implications. Patients and methods: In all, 541 patients with available receptor statuses from both primary tumor and metastatic lesion treated at Heidelberg and Tuebingen University Hospitals between 1982 and 2018 were included. Results: Statistically significant discordance rates of 14% and 32% were found for ER and PR. HER2 status was statistically insignificantly discordant in 15% of patients. Gain in HER2 positivity was associated with an improved overall survival, whereas loss of HR positivity was associated with worse overall survival. Antiendocrine treatment differed in 20% of cases before and after biopsy and HER2-directed treatment in 14% of cases. Conclusions: Receptor statuses are discordant between primary tumor and metastasis in a considerable fraction of patients with metastatic breast cancer. Next to a highly presumed predictive value with respect to efficacy of endocrine and HER2-targeted therapy, discordance seems to provide prognostically relevant information. Where feasible, metastatic lesions should be biopsied in accordance with current guidelines.
- Open Access
Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer
Detection of circulating tumor cells (CTC) can distinguish between aggressive and indolent metastatic disease in breast cancer patients and is thus considered an independent, negative prognostic factor. A clear decline in CTCs is observed in patients who respond to systemic therapy. Nevertheless, CTCs can decrease in patients experiencing disease progression during systemic therapy, too. This study aims to determine the differences between CTC decline in patients responding to therapy and those in whom disease is progressing. Therefore, CTC values were compared at the start and after one cycle of a new line of systemic therapy. In all, 108 initially CTC-positive patients (with ≥5 intact CTCs in 7.5 mL blood) were enrolled in this study and intact and apoptotic CTCs were measured via the CellSearch® system. A cut-off analysis was performed using Youden’s J statistics to differentiate between CTC change in the two groups. Here, 64 (59.3%) patients showed stable disease or partial response vs. 44 (40.7%) presenting disease progression. Median overall survival was 23 (range: 4–92) vs. 7 (2–43) months (p < 0.001). Median intact CTC count at enrollment was 15.0 (5–2760) vs. 30.5 (5–200000) cells (p = 0.39) and 2.5 (0–420) vs. 8.5 (0–15000) cells after one cycle of systemic therapy (p = 0.001). Median apoptotic CTC count at enrollment was 10.5 (0–1500) vs. 9 (0–800) cells (p = 0.475) and 1 (0–200) vs. 3 (0–250) cells after one cycle of systemic therapy (p = 0.01). A 50% reduction in baseline apoptotic CTC count represents the optimal cut-off to differentiate between therapy response and disease progression. An apoptotic CTC reduction of ≤10% is 74% specific for early disease progression.
Open AccessCut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer
Detection of circulating tumor cells (CTC) can distinguish between aggressive and indolent metastatic disease in breast cancer patients and is thus considered an independent, negative prognostic factor. A clear decline in CTCs is observed in patients who respond to systemic therapy. Nevertheless, CTCs can decrease in patients experiencing disease progression during systemic therapy, too. This study aims to determine the differences between CTC decline in patients responding to therapy and those in whom disease is progressing. Therefore, CTC values were compared at the start and after one cycle of a new line of systemic therapy. In all, 108 initially CTC-positive patients (with ≥5 intact CTCs in 7.5 mL blood) were enrolled in this study and intact and apoptotic CTCs were measured via the CellSearch® system. A cut-off analysis was performed using Youden’s J statistics to differentiate between CTC change in the two groups. Here, 64 (59.3%) patients showed stable disease or partial response vs. 44 (40.7%) presenting disease progression. Median overall survival was 23 (range: 4–92) vs. 7 (2–43) months (p < 0.001). Median intact CTC count at enrollment was 15.0 (5–2760) vs. 30.5 (5–200000) cells (p = 0.39) and 2.5 (0–420) vs. 8.5 (0–15000) cells after one cycle of systemic therapy (p = 0.001). Median apoptotic CTC count at enrollment was 10.5 (0–1500) vs. 9 (0–800) cells (p = 0.475) and 1 (0–200) vs. 3 (0–250) cells after one cycle of systemic therapy (p = 0.01). A 50% reduction in baseline apoptotic CTC count represents the optimal cut-off to differentiate between therapy response and disease progression. An apoptotic CTC reduction of ≤10% is 74% specific for early disease progression.
- Open Access
- 21 March 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (6) , 2161
The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer
Circulating tumor cell (CTC) detection is a prognostic factor in the metastatic breast cancer (MBC) setting. Discrepancies in primary (PT) and metastatic tumor (MT) genetic profiles are also of prognostic importance. Our study aimed to compare the CTC statuses and prognoses between those with subtype stable MBCs and MBCs with specific biomarker conversions. The study enrolled 261 MBC patients, treated at the National Center for Tumor Diseases, Heidelberg, Germany in a five-year period. All underwent PT and MT biopsies and subsequent CTC enumeration before the initiation of systemic therapy. ER and HER2 statuses of the PTs and MTs were determined and progression free survivals (PFSs) and overall survivals (OSs) were recorded. We compared CTC statuses, CTC counts, PFSs and OSs between subgroups of patients with different receptor change patterns. Patients who had tumors that converted to triple negative MTs had the shortest median OSs, while HER2 expression was not associated with a shorter median OS. No significant differences in PFSs and OSs have been demonstrated by Kaplan-Meier curve comparisons in any of the subgroup analyses. CTC counts were similar in all subgroups. CTCs were comparably less frequently detected in patients with a stable HER2 expression. Similar proportions of CTC positives were observed in all other subtype change pattern subgroups, barring the aforementioned HER2 stable subgroup. The detection of CTCs was of no appreciable prognostic value in different receptor change pattern subgroups in our cohort.
- 21 March 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (6) , 2161
Open AccessThe Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer
Circulating tumor cell (CTC) detection is a prognostic factor in the metastatic breast cancer (MBC) setting. Discrepancies in primary (PT) and metastatic tumor (MT) genetic profiles are also of prognostic importance. Our study aimed to compare the CTC statuses and prognoses between those with subtype stable MBCs and MBCs with specific biomarker conversions. The study enrolled 261 MBC patients, treated at the National Center for Tumor Diseases, Heidelberg, Germany in a five-year period. All underwent PT and MT biopsies and subsequent CTC enumeration before the initiation of systemic therapy. ER and HER2 statuses of the PTs and MTs were determined and progression free survivals (PFSs) and overall survivals (OSs) were recorded. We compared CTC statuses, CTC counts, PFSs and OSs between subgroups of patients with different receptor change patterns. Patients who had tumors that converted to triple negative MTs had the shortest median OSs, while HER2 expression was not associated with a shorter median OS. No significant differences in PFSs and OSs have been demonstrated by Kaplan-Meier curve comparisons in any of the subgroup analyses. CTC counts were similar in all subgroups. CTCs were comparably less frequently detected in patients with a stable HER2 expression. Similar proportions of CTC positives were observed in all other subtype change pattern subgroups, barring the aforementioned HER2 stable subgroup. The detection of CTCs was of no appreciable prognostic value in different receptor change pattern subgroups in our cohort.
- 27 October 2017
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
- Vol. 221 (S 01) , FV09-4
Eine intrauterine, fetale Herunterregulation des Insulinrezeptors ist im Rattenmodell mit einem letalen Hydrops fetalis assoziiert, der durch eine mütterliche Hyperglykämie gelindert werden kann
Fragestellung: Eine Herunterregulation des Insulinrezeptors (IR) führt im Erwachsenenalter zu Insulinresistenz und Diabetes und ist mit erhöhter Morbidität und Mortalität verbunden. Unser Ziel war es, den Effekt der Herunterregulation des IR auf die fetale Entwicklung zu untersuchen. Methodik: Die Experimente wurden mit transgenen, heterozygoten TetO-Ratten durchgeführt. Diese besitzen eine Doxycyclin (DOX)-abhängige shRNA, welche über RNA-Interferenz die Expression des IR vermindert. Somit wird durch die Gabe von DOX eine Herunterregulation des IR im gesamten Organismus hervorgerufen und eine Insulinresistenz mit konsekutiver Hyperglykämie induziert. Weibliche Wildtyp-Ratten (WT) wurden mit männlichen TetO-Ratten verpaart und weibliche TetO-Ratten wurden mit männlichen WT-Ratten verpaart. Die Muttertiere (sowohl WT als auch TetO) erhielten DOX für einige Tage vor Empfängnis sowie am Ende der Schwangerschaft. DOX geht über die Plazenta in den Fetus über. Ergebnis: WT Muttertiere und deren Feten waren erwartungsgemäß normoglykäm. TetO-Muttertiere und deren Feten waren, ebenfalls erwartungsgemäß, hyperglykäm. Etwa 50% der Nachkommen jedes Muttertiers waren TetO-positiv. TetO-positive Feten zeigten eine Herunterregulation des IR, da das den Müttern applizierte Doxycyclin auf die Feten übergangen war. TetO-positive Feten in der Nachkommenschaft normoglykämer WT Muttertiere überlebten die ersten postnatalen Stunden nicht. Sie zeigten einen Hydrops mit Ascites, Pleuraerguß und Hautödem. Im Gegensatz dazu überlebten TetO-positive Feten von hyperglykämen Muttertieren und entwickelten sich unauffällig. Schlussfolgerung: Eine fetale, intrauterine Herunterregulation des IR ist mit einem letalen Hydrops fetalis assoziiert. Eine mütterliche und fetale Hyperglykämie verhindern die Entwicklung dieses Hydrops. Unsere Hypothese für dieses Phänomen ist, dass Endothelzellen eine kritische Glukosemenge benötigen um ihre Barrierefunktion aufrechterhalten zu können. Im Falle einer Herunterregulation des IR kann weniger Glukose aus dem Blut in die Endothelzellen aufgenommen werden, was zu einer endothelialen Funktionsstörung mit Hydrops führt. Im Falle einer fetalen Hyperglykämie (bedingt durch maternale Hyperglykämie) werden die Endothelzellen aufgrund eines höheren Glukosegradienten zwischen Blut und Endothelzellen immer noch ausreichend mit Glukose versorgt, wodurch ihre Funktion aufrechterhalten werden kann. Im Erwachsenenalter gibt es dieses Szenario einer Herunterregulation des IRs mit Normoglykämie nur sehr selten, da üblicherweise eine Insulinresistenz mit einer Hyperglykämie einhergeht. Unser vorgestelltes Szenario kann somit typischerweise nur in der intrauterinen Situation entstehen, wenn die Glukoseversorgung des Blutes extern bestimmt wird. Unsere Hypothese könnte einen Teil der in der Klinik als idiopathisch bezeichneten Fälle von Hydrops fetalis erklären. Genetische Untersuchungen bei Menschen sind nötig, um die Hypothese zu prüfen.
- 27 October 2017
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
- Vol. 221 (S 01) , FV09-4
Eine intrauterine, fetale Herunterregulation des Insulinrezeptors ist im Rattenmodell mit einem letalen Hydrops fetalis assoziiert, der durch eine mütterliche Hyperglykämie gelindert werden kann
Fragestellung: Eine Herunterregulation des Insulinrezeptors (IR) führt im Erwachsenenalter zu Insulinresistenz und Diabetes und ist mit erhöhter Morbidität und Mortalität verbunden. Unser Ziel war es, den Effekt der Herunterregulation des IR auf die fetale Entwicklung zu untersuchen. Methodik: Die Experimente wurden mit transgenen, heterozygoten TetO-Ratten durchgeführt. Diese besitzen eine Doxycyclin (DOX)-abhängige shRNA, welche über RNA-Interferenz die Expression des IR vermindert. Somit wird durch die Gabe von DOX eine Herunterregulation des IR im gesamten Organismus hervorgerufen und eine Insulinresistenz mit konsekutiver Hyperglykämie induziert. Weibliche Wildtyp-Ratten (WT) wurden mit männlichen TetO-Ratten verpaart und weibliche TetO-Ratten wurden mit männlichen WT-Ratten verpaart. Die Muttertiere (sowohl WT als auch TetO) erhielten DOX für einige Tage vor Empfängnis sowie am Ende der Schwangerschaft. DOX geht über die Plazenta in den Fetus über. Ergebnis: WT Muttertiere und deren Feten waren erwartungsgemäß normoglykäm. TetO-Muttertiere und deren Feten waren, ebenfalls erwartungsgemäß, hyperglykäm. Etwa 50% der Nachkommen jedes Muttertiers waren TetO-positiv. TetO-positive Feten zeigten eine Herunterregulation des IR, da das den Müttern applizierte Doxycyclin auf die Feten übergangen war. TetO-positive Feten in der Nachkommenschaft normoglykämer WT Muttertiere überlebten die ersten postnatalen Stunden nicht. Sie zeigten einen Hydrops mit Ascites, Pleuraerguß und Hautödem. Im Gegensatz dazu überlebten TetO-positive Feten von hyperglykämen Muttertieren und entwickelten sich unauffällig. Schlussfolgerung: Eine fetale, intrauterine Herunterregulation des IR ist mit einem letalen Hydrops fetalis assoziiert. Eine mütterliche und fetale Hyperglykämie verhindern die Entwicklung dieses Hydrops. Unsere Hypothese für dieses Phänomen ist, dass Endothelzellen eine kritische Glukosemenge benötigen um ihre Barrierefunktion aufrechterhalten zu können. Im Falle einer Herunterregulation des IR kann weniger Glukose aus dem Blut in die Endothelzellen aufgenommen werden, was zu einer endothelialen Funktionsstörung mit Hydrops führt. Im Falle einer fetalen Hyperglykämie (bedingt durch maternale Hyperglykämie) werden die Endothelzellen aufgrund eines höheren Glukosegradienten zwischen Blut und Endothelzellen immer noch ausreichend mit Glukose versorgt, wodurch ihre Funktion aufrechterhalten werden kann. Im Erwachsenenalter gibt es dieses Szenario einer Herunterregulation des IRs mit Normoglykämie nur sehr selten, da üblicherweise eine Insulinresistenz mit einer Hyperglykämie einhergeht. Unser vorgestelltes Szenario kann somit typischerweise nur in der intrauterinen Situation entstehen, wenn die Glukoseversorgung des Blutes extern bestimmt wird. Unsere Hypothese könnte einen Teil der in der Klinik als idiopathisch bezeichneten Fälle von Hydrops fetalis erklären. Genetische Untersuchungen bei Menschen sind nötig, um die Hypothese zu prüfen.